926TiP Phase II trial of enoblituzumab plus retifanlimab or tebotelimab in first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M SCCHN)

Line Treatment ◽

First Line ◽

123MO Monalizumab, cetuximab and durvalumab in first-line treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): A phase II trial

Annals of Oncology ◽

10.1016/j.annonc.2021.10.142 ◽

2021 ◽

Vol 32 ◽

pp. S1432

Author(s):

D.A. Colevas ◽

K. Misiukiewicz ◽

A.T. Pearson ◽

J. Fayette ◽

J.R. Bauman ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Metastatic Squamous Cell Carcinoma ◽

Cetuximab, docetaxel, and cisplatin (TPEx) as first-line treatment in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): First results of phase II trial GORTEC 2008-03.

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.5567 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 5567-5567 ◽

Cited By ~ 8

Author(s):

J. Guigay ◽

J. Fayette ◽

A. Dillies ◽

C. Sire ◽

J. N. Kerger ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

First Results ◽

Phase II trial of the irreversible oral pan-HER inhibitor PF-00299804 (PF) as first-line treatment in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.5531 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 5531-5531 ◽

Cited By ~ 3

Author(s):

C. Le Tourneau ◽

E. Winquist ◽

S. J. Hotte ◽

S. A. Laurie ◽

D. Soulieres ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Phase II trial of the irreversible oral pan-human EGF receptor (HER) inhibitor PF-00299804 (PF) as first-line treatment in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.5561 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 5561-5561 ◽

Cited By ~ 5

Author(s):

L. L. Siu ◽

S. J. Hotte ◽

S. A. Laurie ◽

S. Singh ◽

E. Winquist ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Phase Ii ◽

Squamous Cell ◽

Egf Receptor ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study

Annals of Oncology ◽

10.1093/annonc/mdv268 ◽

2015 ◽

Vol 26 (9) ◽

pp. 1941-1947 ◽

Cited By ~ 64

Author(s):

J. Guigay ◽

J. Fayette ◽

A.F. Dillies ◽

C. Sire ◽

J.N. Kerger ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Phase Ii ◽

Squamous Cell ◽

Line Treatment ◽

First Line ◽

Multicenter Phase ◽

FDA approves pembrolizumab for first-line treatment of head and neck squamous cell carcinoma

Case Medical Research ◽

10.31525/cmr-14e3317 ◽

2019 ◽

Author(s):

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Line Treatment ◽

First Line ◽

Cetuximab, Docetaxel and Cisplatin as First-Line Treatment in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Results of the GORTEC 2014-01 TPExtreme Randomized Trial

SSRN Electronic Journal ◽

10.2139/ssrn.3700967 ◽

2020 ◽

Author(s):

Joël Guigay ◽

Anne Aupérin ◽

Jerome Fayette ◽

Esma Saada-Bouzid ◽

Cédrik Lafond ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Randomized Trial ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Line Treatment ◽

First Line ◽

972TiP Phase II study of intratumoral MK-1454 plus pembrolizumab compared with pembrolizumab monotherapy as first-line treatment for metastatic or unresectable, recurrent head and neck squamous cell carcinoma

Annals of Oncology ◽

10.1016/j.annonc.2020.08.1087 ◽

2020 ◽

Vol 31 ◽

pp. S683

Author(s):

K.J. Harrington ◽

W.N. William ◽

A. Khilnani ◽

A.P. Algazi

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

Recurrent Head ◽

Randomized Phase II Trial of Capecitabine Plus Cisplatin Versus Paclitaxel as First Line Treatment for Metastatic Esophageal Squamous Cell Carcinoma

Annals of Oncology ◽

10.1093/annonc/mdt203.59 ◽

2013 ◽

Vol 24 ◽

pp. iv53

Author(s):

Su Jin Lee ◽

Silvia Park ◽

Wonjin Chang ◽

Jung Yong Hong ◽

Moon Ki Choi ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Esophageal Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

Capecitabine and lapatinib for the first-line treatment of metastatic/recurrent head and neck squamous cell carcinoma

Cancer ◽

10.1002/cncr.30067 ◽

2016 ◽

Vol 122 (15) ◽

pp. 2350-2355 ◽

Cited By ~ 10

Author(s):

Jared M. Weiss ◽

Stephen Bagley ◽

Wei-Ting Hwang ◽

Joshua Bauml ◽

Juneko Grilley Olson ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Line Treatment ◽

First Line ◽

Recurrent Head ◽